BERGEN, NORWAY: BerGenBio ASA, a clinical-stage biopharmaceutical company, announced today the appointment of Anders Tullgren to succeed Sveinung Hole as Chairman of the Board of Directors, effective Thursday.
Sveinung Hole has been Chairman of the Board since March 2019 and will continue to serve as a Board Member.
Anders Tullgren has over 35 years of global experience in both large pharmaceutical and small/mid-size biotech environments, with senior leadership roles in the United States, Germany, France, the United Kingdom, and the Nordic region.
He spent over 20 years at Bristol Myers Squibb, most recently as President, Intercontinental Region at the firm, with responsibility across 30 countries, 5,000 employees and a turnover of over 2.7 billion USD.
Anders has in his career worked with several oncology products and was leading the successful launch of BMS immuno-oncology portfolio in the intercontinental region.
Anders is an experienced non-executive director with current Board and Chair positions at Branding Science Ltd (UK), Xbrane Biopharma AB (Sweden), Farmalisto (Panama) and Dizlin Pharmaceuticals AB (Sweden). He holds an MSc in Pharmaceutical Studies from Uppsala University (Sweden) and a Diploma in Marketing & Business Administration from MIS (Sweden).
Martin Olin, Chief Executive Officer of BerGenBio, commented: “We’re delighted to welcome Anders Tullgren as Chairman. Anders’ experience and deep knowledge of development, commercialization and growth planning is highly valuable in our journey to provide novel therapeutic modalities to treat severe diseases. I’d like to take this opportunity to thank Sveinung for his excellent leadership of the Board during the past few years, which have seen a number of important milestones as we progress our clinical trials.”
On his appointment as Chairman of the Board, Anders Tullgren said: “It is an honor to have the opportunity to take on the role of Chairman and to work within an incredible company and alongside a strong leadership team. I look forward to supporting BerGenBio as it advances the progression of its lead candidate, bemcentinib, and working closely with Martin, Sveinung and the rest of the Board.”